Covered recipient · General Payments record
JULIE E BRADFORD
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,387.97
- Reported across 82 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $292.63 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $76.66 | 4 |
| Novo Nordisk AS | $54.03 | 3 |
| BioMarin Pharmaceutical Inc. | $23.57 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $20.78 | 1 |
| EISAI INC. | $18.65 | 1 |
| Lilly USA, LLC | $18.62 | 1 |
| Phathom Pharmaceuticals, Inc. | $18.35 | 1 |
| Merck Sharp & Dohme Corporation | $16.88 | 1 |
| PFIZER INC. | $16.47 | 1 |
| GlaxoSmithKline, LLC. | $14.47 | 1 |
| Acerta Pharma LLC | $14.15 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.47 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106812336 | CMS |
| ABBVIE INC. | $17.89 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106812338 | CMS |
| ABBVIE INC. | $23.85 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106812340 | CMS |
| ABBVIE INC. | $18.45 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106812342 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.15 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105487133 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $20.78 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086306568 | CMS |
| BioMarin Pharmaceutical Inc. | $23.57 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127061272 | CMS |
| Eisai Inc. | $18.65 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110807200 | CMS |
| GlaxoSmithKline, LLC. | $14.47 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115905323 | CMS |
| Lilly USA, LLC | $18.62 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135729401 | CMS |
| Merck Sharp & Dohme LLC | $16.88 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141911798 | CMS |
| Novo Nordisk Inc | $17.00 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100364089 | CMS |
| Novo Nordisk Inc | $21.87 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100352950 | CMS |
| Novo Nordisk Inc | $15.16 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100327556 | CMS |
| PFIZER INC. | $16.47 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131503638 | CMS |
| Phathom Pharmaceuticals, Inc. | $18.35 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151150585 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.